Side-by-side · Research reference

CrystagenvsOvagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BTheoreticalHUMAN-REVIEWED2/42 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

01Mechanism of Action

Parameter

Crystagen

Ovagen

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Ovarian tissue chromatin complexes

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

Presumed physiological — Khavinson peptides described as regulatory, not replacement

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

Ovagen

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

Evidence basis

Animal / mechanistic

Theoretical / Russian-tradition

Route

Subcutaneous (presumed from bioregulator class)

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

Frequency

Unknown — bioregulator protocols variable

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Duration

Unknown — chronic administration presumed in animal models

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

Half-life

Not reported

—

04Side Effects & Safety

Parameter

Crystagen

Ovagen

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Reported adverse events

—

None documented in indexed literature

Theoretical hormonal effects

—

Ovarian stimulation — monitor for estrogen-sensitive conditions

Injection site reaction

—

Possible mild erythema (SQ route)

Long-term safety

—

Unknown — no PubMed-indexed RCTs

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

05Administration Protocol

Parameter

Crystagen

Ovagen

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

Ovagen

— no documented stacks